Eli Lilly's newly launched weight-loss pill was prescribed 1,390 times in the U.S. ​in its first week of sales, according to ...

The UAE has approved Foundayo (orforglipron), Eli Lilly's once-daily oral obesity pill, becoming one of the first countries ...

The U.S. Food and Drug Administration is asking Eli Lilly and Company, the leading manufacturer of GLP-1s, for additional ...

The thriving market in online, counterfeit GLP-1 drugs that do not meet FDA criteria poses serious risks to consumers.

Struggling with hair loss? Whether it's due to menopause, postpartum changes, or stress, the right supplements can make a ...

The U.S. Food and Drug Administration (FDA) has told Eli Lilly to study possible heart, liver and other risks tied to its new ...

The Food and Drug Administration on April 1 approved Eli Lilly's new weight-loss pill, giving consumers a second option in the growing non-injectable GLP-1 weight-loss drug market. Lilly said it will ...

Federal regulators on Wednesday approved Eli Lilly’s new weight-loss pill, a second daily oral medication to treat obesity and other weight-related conditions. The Food and Drug Administration granted ...

The brief reign of Novo Nordisk’s Wegovy pill as the lone oral GLP-1 approved for obesity has ended as Eli Lilly’s orforglipron cruised past an FDA green light Wednesday. Now christened Foundayo, the ...

The FDA approved a new GLP-1 pill called Foundayo (orforglipron) for adults with obesity or who are overweight and have weight-related health issues. Unlike the Wegovy pill, Foundayo has no food or ...

If you've been following the weight-loss medication revolution, you've likely heard about Wegovy injections. But now there's a new option that might be even more appealing: a once-daily pill. The FDA ...

Teens in the U.S. are obtaining medication abortion pills through telehealth, and young people age 18 to 24 are ordering medication abortion at much higher rates than older adults. Those are the key ...